CL vs EMR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

CL

42.8
AI Score
VS
CL Wins

EMR

34.8
AI Score

Investment Advisor Scores

CL

43score
Recommendation
HOLD

EMR

35score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric CL EMR Winner
Forward P/E 20.9644 21.4592 CL
PEG Ratio 1.566 1.7818 CL
Revenue Growth 4.9% 7.0% EMR
Earnings Growth -5.5% 23.0% EMR
Tradestie Score 42.8/100 34.8/100 CL
Profit Margin 9.7% 13.8% EMR
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY CL

Relative Price Performance (Last 90 Days)

CL 1M: -6.3% · 3M: -9.6% EMR 1M: +8.1% · 3M: +13.8%

Current Technical Phase

CL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 33

RSI (14): 33.2 · Price: $84.39

EMR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 62

RSI (14): 62.0 · Price: $161.03

Fundamentals Snapshot

Metric CL EMR
Market Cap — —
Forward P/E 20.6 21.8
Trailing P/E 33.6 34.4
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.6% 0.5%
Operating Margin 0.2% 0.3%
EPS 2.54 4.51
Dividend Yield 0.02% 0.01%

Frequently Asked Questions

Based on our detailed analysis, CL is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.